(AVTR) Avantor - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 5.388m USD | Total Return: -47.5% in 12m

Lab Supplies, Chemicals, Equipment, Services
Total Rating 24
Safety 82
Buy Signal -0.69
Medical Instruments & Supplies
Industry Rotation: -9.7
Market Cap: 5.39B
Avg Turnover: 62.3M USD
ATR: 4.67%
Peers RS (IBD): 1.7
Risk 5d forecast
Volatility54.2%
Rel. Tail Risk-15.4%
Reward TTM
Sharpe Ratio-0.95
Alpha-68.65
Character TTM
Beta0.773
Beta Downside0.431
Drawdowns 3y
Max DD73.25%
CAGR/Max DD-0.39
EPS (Earnings per Share) EPS (Earnings per Share) of AVTR over the last years for every Quarter: "2021-03": 0.35, "2021-06": 0.35, "2021-09": 0.35, "2021-12": 0.36, "2022-03": 0.38, "2022-06": 0.37, "2022-09": 0.34, "2022-12": 0.32, "2023-03": 0.29, "2023-06": 0.28, "2023-09": 0.25, "2023-12": 0.25, "2024-03": 0.22, "2024-06": 0.25, "2024-09": 0.26, "2024-12": 0.27, "2025-03": 0.23, "2025-06": 0.24, "2025-09": 0.22, "2025-12": 0.22, "2026-03": 0,
EPS CAGR: -52.10%
EPS Trend: -76.9%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of AVTR over the last years for every Quarter: 2021-03: 1785.6, 2021-06: 1858.6, 2021-09: 1834.3, 2021-12: 1907.6, 2022-03: 1950.4, 2022-06: 1910.5, 2022-09: 1856.5, 2022-12: 1795, 2023-03: 1780.3, 2023-06: 1743.9, 2023-09: 1720.2, 2023-12: 1722.8, 2024-03: 1679.8, 2024-06: 1702.8, 2024-09: 1714.4, 2024-12: 1686.6, 2025-03: 1581.4, 2025-06: 1683.4, 2025-09: 1623.8, 2025-12: 1663.6, 2026-03: null,
Rev. CAGR: -4.15%
Rev. Trend: -90.0%
Last SUE: 1.54
Qual. Beats: 1

Warnings

High Debt/EBITDA (25.8) with thin interest coverage (-1.6)

Interest Coverage Ratio -1.6 is critical

Choppy

Tailwinds

No distinct edge detected

Description: AVTR Avantor

Avantor, Inc. (AVTR) supplies essential products and services to biopharma, healthcare, education, government, and advanced technology sectors globally.

The companys offerings include materials and consumables like chemicals, lab supplies, and customized single-use assemblies. This business model focuses on providing critical components for scientific research and manufacturing.

Avantor also provides equipment, such as filtration systems, incubators, and analytical instruments. Additionally, it offers services including onsite lab support, procurement, and biopharmaceutical material development, reflecting a comprehensive approach to supporting scientific and industrial operations.

The Life Sciences Tools & Services sub-industry, where Avantor operates, is characterized by its foundational role in drug discovery, development, and manufacturing.

For more detailed financial analysis, consider exploring Avantors profile on ValueRay.

Headlines to Watch Out For
  • Biopharma research spending directly impacts Avantors consumables sales
  • Global healthcare investment drives demand for equipment and services
  • Supply chain disruptions increase raw material and logistics costs
  • Regulatory changes in life sciences affect product development and sales
Piotroski VR‑10 (Strict) 3.5
Net Income: -530.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.52 > 1.0
NWC/Revenue: 16.37% < 20% (prev 2.05%; Δ 14.31% < -1%)
CFO/TA 0.05 > 3% & CFO 623.8m > Net Income -530.2m
Net Debt (3.58b) to EBITDA (138.7m): 25.82 < 3
Current Ratio: 1.78 > 1.5 & < 3
Outstanding Shares: last quarter (679.3m) vs 12m ago -0.50% < -2%
Gross Margin: 32.65% > 18% (prev 0.34%; Δ 3.23k% > 0.5%)
Asset Turnover: 54.81% > 50% (prev 56.00%; Δ -1.19% > 0%)
Interest Coverage Ratio: -1.60 > 6 (EBITDA TTM 138.7m / Interest Expense TTM 169.8m)
Altman Z'' 1.86
A: 0.09 (Total Current Assets 2.45b - Total Current Liabilities 1.38b) / Total Assets 11.79b
B: 0.14 (Retained Earnings 1.67b / Total Assets 11.79b)
C: -0.02 (EBIT TTM -271.5m / Avg Total Assets 11.95b)
D: 0.91 (Book Value of Equity 5.64b / Total Liabilities 6.23b)
Altman-Z'' Score: 1.86 = BBB
Beneish M -3.09
DSRI: 1.08 (Receivables 1.07b/1.03b, Revenue 6.55b/6.78b)
GMI: 1.03 (GM 32.65% / 33.60%)
AQI: 0.95 (AQ_t 0.73 / AQ_t-1 0.76)
SGI: 0.97 (Revenue 6.55b / 6.78b)
TATA: -0.10 (NI -530.2m - CFO 623.8m) / TA 11.79b)
Beneish M-Score: -3.09 (Cap -4..+1) = AA
What is the price of AVTR shares? As of April 08, 2026, the stock is trading at USD 8.00 with a total of 6,919,033 shares traded.
Over the past week, the price has changed by +2.04%, over one month by -1.84%, over three months by -33.77% and over the past year by -47.47%.
Is AVTR a buy, sell or hold? Avantor has received a consensus analysts rating of 3.76. Therefor, it is recommend to hold AVTR.
  • StrongBuy: 6
  • Buy: 4
  • Hold: 11
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AVTR price?
Analysts Target Price 10.9 36%
Avantor (AVTR) - Fundamental Data Overview as of 06 April 2026
P/E Forward = 8.2988
P/S = 0.8224
P/B = 0.9598
Revenue TTM = 6.55b USD
EBIT TTM = -271.5m USD
EBITDA TTM = 138.7m USD
Long Term Debt = 3.92b USD (from longTermDebt, last quarter)
Short Term Debt = 30.8m USD (from shortTermDebt, last quarter)
Debt = 3.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.58b USD (from netDebt column, last quarter)
Enterprise Value = 8.97b USD (5.39b + Debt 3.95b - CCE 365.4m)
Interest Coverage Ratio = -1.60 (Ebit TTM -271.5m / Interest Expense TTM 169.8m)
EV/FCF = 18.12x (Enterprise Value 8.97b / FCF TTM 495.0m)
FCF Yield = 5.52% (FCF TTM 495.0m / Enterprise Value 8.97b)
FCF Margin = 7.55% (FCF TTM 495.0m / Revenue TTM 6.55b)
Net Margin = -8.09% (Net Income TTM -530.2m / Revenue TTM 6.55b)
Gross Margin = 32.65% ((Revenue TTM 6.55b - Cost of Revenue TTM 4.41b) / Revenue TTM)
Gross Margin QoQ = 31.49% (prev 32.42%)
Tobins Q-Ratio = 0.76 (Enterprise Value 8.97b / Total Assets 11.79b)
Interest Expense / Debt = 1.01% (Interest Expense 40.0m / Debt 3.95b)
Taxrate = 35.15% (28.4m / 80.8m)
NOPAT = -176.1m (EBIT -271.5m * (1 - 35.15%)) [loss with tax shield]
Current Ratio = 1.78 (Total Current Assets 2.45b / Total Current Liabilities 1.38b)
Debt / Equity = 0.71 (Debt 3.95b / totalStockholderEquity, last quarter 5.57b)
Debt / EBITDA = 25.82 (Net Debt 3.58b / EBITDA 138.7m)
Debt / FCF = 7.23 (Net Debt 3.58b / FCF TTM 495.0m)
Total Stockholder Equity = 5.88b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.44% (Net Income -530.2m / Total Assets 11.79b)
RoE = -9.02% (Net Income TTM -530.2m / Total Stockholder Equity 5.88b)
RoCE = -2.77% (EBIT -271.5m / Capital Employed (Equity 5.88b + L.T.Debt 3.92b))
 RoIC = -1.78% (negative operating profit) (NOPAT -176.1m / Invested Capital 9.92b)
 WACC = 5.30% (E(5.39b)/V(9.33b) * Re(8.70%) + D(3.95b)/V(9.33b) * Rd(1.01%) * (1-Tc(0.35)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF] Terminal Value 85.43% ; FCFF base≈573.8m ; Y1≈526.3m ; Y5≈469.9m
[DCF] Fair Price = 15.57 (EV 14.11b - Net Debt 3.58b = Equity 10.53b / Shares 676.1m; r=6.0% [WACC]; 5y FCF grow -10.37% → 3.0% )
EPS Correlation: -76.92 | EPS CAGR: -52.10% | SUE: -4.0 | # QB: 0
Revenue Correlation: -90.03 | Revenue CAGR: -4.15% | SUE: 1.54 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.20 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-12 | Analysts=16
EPS current Year (2026-12-31): EPS=0.79 | Chg7d=+0.000 | Chg30d=-0.001 | Revisions Net=-16 | Growth EPS=-12.3% | Growth Revenue=-0.9%
EPS next Year (2027-12-31): EPS=0.85 | Chg7d=+0.006 | Chg30d=+0.004 | Revisions Net=-8 | Growth EPS=+7.8% | Growth Revenue=+2.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 12 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle